Quick Answer
CORCEPT THERAPEUTICS INC reported Research And Development Expense of $254.91 million for the year ending 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +3.2% in Research And Development Expense from 2024 to 2025.
- This data is from CORCEPT THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CORCEPT THERAPEUTICS INC's Research And Development Expense has grown by 1,669.9%.
- Historical annual values: Fiscal year 2025: $254.91 million | Fiscal year 2024: $246.89 million | Fiscal year 2023: $184.35 million | Fiscal year 2022: $130.99 million | Fiscal year 2021: $113.86 million | Fiscal year 2020: $114.76 million | Fiscal year 2019: $89.02 million | Fiscal year 2018: $75.25 million | Fiscal year 2017: $40.38 million | Fiscal year 2016: $23.84 million | Fiscal year 2015: $15.42 million | Fiscal year 2014: $18.37 million | Fiscal year 2013: $20.47 million | Fiscal year 2012: $14.07 million | Fiscal year 2011: $21.00 million | Fiscal year 2010: $18.95 million | Fiscal year 2009: $14.40 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: